Compare CNDT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | CRBU |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | 51000 | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4M | 192.4M |
| IPO Year | 2016 | 2021 |
| Metric | CNDT | CRBU |
|---|---|---|
| Price | $1.44 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,042,000,000.00 | N/A |
| Revenue This Year | $2.01 | $1.63 |
| Revenue Next Year | $4.06 | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $1.04 |
| 52 Week High | $2.98 | $3.53 |
| Indicator | CNDT | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 39.07 |
| Support Level | $1.33 | $1.75 |
| Resistance Level | $1.60 | $2.02 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 12.10 | 9.15 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.